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Background/Aims
To evaluate the value of a 2-week high dose proton pump inhibitor (PPI) treatment on patients with overlapping non-erosive 
gastroesophageal reflux disease (NERD) and functional dyspepsia (FD).
Methods
Sixty overlapping NERD and FD patients with symptom onset > 3 months prior underwent 24-hour esophageal pH monitoring 
studies. All patients received rabeprazole 20 mg b.i.d. for 2 weeks. The reflux and dyspeptic symptoms were evaluated using 
a symptom questionnaire with 4-point Likert scales before and at the end of treatment. A positive PPI test was defined as 
score improvement in ≥  50% from the baseline in the typical reflux symptoms. 
Results
The prevalence of each reflux and dyspeptic symptom did not differ significantly between patients with positive and negative 
pH tests. After the PPI treatment, epigastric burning, acid regurgitation, heartburn, nausea, vomiting and chest discomfort 
scores were significantly improved compared to pretreatment values (P < 0.05), whereas postprandial abdominal fullness, early 
satiation, belching and food regurgitation were not. The proportion of patients who responded to the PPI treatment did not 
differ significantly between patients with positive and negative pH tests. The sensitivity, specificity, PPV, NPV and accuracy of 
2-week high dose rabeprazole treatment for diagnosing gastroesophageal reflux disease were 47%, 38%, 50%, 35% and 43%, 
respectively. 
Conclusions
The two-week high dose PPI treatment was not effective for early satiation, postprandial abdominal fullness, regurgitation or 
belching symptoms in patients with overlapping NERD and FD. Acid exposure in the distal esophagus could not predict the 
response of symptoms to PPI. In addition, the 2-week PPI test provided limited value for gastroesophageal reflux disease diag-
nosis in patients with overlapping NERD and FD. 
(J Neurogastroenterol Motil 2012;18:174-180)
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Introduction
Dyspeptic symptoms are commonly observed among patients 
with gastroesophageal reflux disease (GERD).
1,2 Patients who 
experience both dyspeptic and GERD symptoms have been re-
ported to have impaired quality of life compared to patients with 
only dyspeptic or GERD symptoms.
1,3 The dyspeptic symptoms 
have heterogeneous presentations that may involve epigastric 
pain, epigastric burning, abdominal fullness, early satiation, nau-
sea, vomiting, belching and are considered to have various under-
lying pathophysiologies.
4-6 Gastric acid has been demonstrated to 
play a role in the pathophysiology of dyspeptic symptoms. Exten-
sive evidence supports the usage of acid-suppressive therapy for 
functional dyspepsia (FD).
7,8 Meta-analysis also revealed sig-
nificant dyspeptic symptom improvement in patients treated with 
proton pump inhibitor (PPI). However, the benefit was observed 
in particular patients with reflux-like or ulcer-like dyspepsia but 
not in the patients with dysmotility-like dyspepsia who had post-
prandial fullness, early satiation, bloating or belching as their 
dominant symptom.
8-11 Various pathophysiological mechanisms 
in the esophagus, stomach and duodenum might induce dyspeptic 
symptoms. Acid reflux into the esophagus might cause dyspepsia 
without reflux symptoms in some patients, which is effectively treat-
ed with acid-secretion inhibitors.
12 Acid in the stomach might also 
provoke symptoms. Increased acid secretion after the injection of 
pentagastrin provokes symptoms in patients with non-ulcer 
dyspepsia.
13 Delayed gastric emptying and impaired gastric accom-
modation have been shown to be associated with abdominal fullness 
and early satiation. Due to various pathophysiologies of these upper 
gastrointestinal (GI) symptoms, the treatment of GERD patients 
with overlapping dyspeptic symptoms remains as a major challenge. 
Previous studies reported that acid-suppressive therapy by 
PPI could delay gastric emptying in humans.
14,15 This may pro-
duce negative effects on some dyspeptic symptoms associated 
with delayed gastric emptying such as postprandial abdominal 
fullness. Therefore, PPI may provide benefits in the treatment of 
acid-related symptoms such as heartburn, acid regurgitation, 
chest discomfort and epigastrium burning/pain but not in 
non-acid related symptoms such as postprandial abdominal full-
ness or early satiety symptoms. However, limited data have been 
published regarding the therapeutic and diagnostic value of 
short-term PPI treatment in patients with overlapping GERD 
and FD. The primary objectives of this study were: (1) to inves-
tigate the response of each individual GERD and dyspeptic 
symptom to treatment with high dose PPI in patients with over-
lapping NERD and FD and (2) to compare the treatment re-
sponses between patients with and without abnormal 24-hour pH 
monitoring. The secondary objective was to compare the 2-week 
PPI test results and the results from 24-hour esophageal pH 
monitoring for the diagnosis of GERD in this patient group.
Materials and Methods
Study Population 
The adult patients, 18-80 years old, who had disturbing typical 
reflux symptoms (heartburn and/or acid regurgitation) and dyspep-
tic symptoms for more than 3 months were evaluated prospectively 
during from 2004 to 2008 at the gastrointestinal clinic, GI motility 
research Unit, King Chulalongkorn Memorial Hospital, Chulalongkorn 
University, Bangkok, Thailand. All patients underwent upper en-
doscopy within 1 month prior to the enrollment. Exclusion criteria 
were as follows: patients who had significant reflux esophagitis 
(Los Angeles classification: grade B, C or D), peptic ulcer or 
esophageal/peptic stricture or gastric cancer visible on upper endos-
copy, alarm features (including persistent dysphagia, unintentional 
weight loss, anemia, GI bleeding and jaundice), irritable bowel syn-
drome, chronic severe constipation, alcohol or drug abuse, preg-
nancy, lactation, diabetes mellitus, neurological diseases, history of 
GI surgery (except appendectomy) and/or had recently taken acid 
suppressants or prokinetics within 1 month prior to the study. This 
study was approved by the institution review board, and all partic-
ipants provided their written informed consent. 
Study Design
All patients were interviewed regarding the presence and se-
verity of each individual esophageal or other upper GI symptom 
including heartburn, acid regurgitation, chest discomfort, post-
prandial abdominal fullness, nausea, vomiting, early satiation, ep-
igastric burning, food regurgitation and belching using a symp-
tom questionnaire. The severity of each of the upper GI symp-
toms was evaluated with a 4-point Likert scale before and at the 
end of treatment (0 = no symptoms, 1 = mild symptoms 
[occasionally symptoms that do not influence daily activities or 
sleeping], 2 = moderate symptoms [occasionally influence daily 
activities but do not induce changes in daily activities or sleeping] 
and 3 = severe [influence on daily activities and induce changes 
in daily activities or sleeping]).
16 After at least 6 hours of over-
night fasting, all patients underwent water perfusion esophageal Chatchai Kriengkirakul, et al
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Figure 1. Baseline prevalence of each upper gastrointestinal symptom 
among patients with positive and negative 24-hour esophageal pH 
monitoring results (*P < 0.05).
Table 1. Baseline Patient Characteristics of 60 Patients
       Patients characteristics
Gender (male:female [%]) 22:78
Age (yr) 49.2 ± 13.4
BMI 23.6  ±  3.3
Alcohol drinking (n [%])   8 (13.0)
Smoking (n [%])   6 (10.0)
Symptoms (n [%])
  Heartburn 42 (70.0)
  Acid regurgitation 47 (78.3)
  Chest discomfort 43 (71.7)
  Epigastric burning 43 (71.7)
  Postprandial fullness  51 (85.0)
  Early satiation 37 (61.7)
  Belching  47 (78.3)
  Nausea  26 (43.3)
  Vomiting  13 (21.7)
  Food regurgitation 38 (63.0)
24-hour pH monitoring result
  Positive 34 (56.7)
  Negative 26 (43.3)
Esophageal manometry result
  Normal 33 (55.0)
  Abnormal 27 (45.0)
    Ineffective esophageal motility disorder 10 (16.7)
    Diffuse esophageal spasm 5 (8.3)
    Nutcracker esophagus 5 (8.3)
    Hypertensive LES pressure 2 (3.3)
    Scleroderma-like esophagus 2 (3.3)
    Impaired LES relaxation 2 (3.3)
    Hypotensive LES pressure 1 (1.8)
BMI, body mass index; LES, lower esophageal sphincter.
manometry for location of the lower esophageal sphincter. The 
pH catheter (GeroFlex
TM/M; Sierra Scientific Instruments, CA, 
USA ) was placed with a pH sensor located at 5 cm above the 
lower esophageal sphincter for ambulatory, 24-hour esophageal 
pH monitoring (Digitrapper; Medtronic A/S, Skovlunde, 
Denmark). After the tests, all patients received Rabeprazole 
(Pariet
Ⓡ; Easai Co., Ltd, Bangkok, Thailand) 20 mg twice daily 
for 2 weeks. A positive 24-hour esophageal pH monitoring test 
was defined as a total percentage of time with pH < 4 for greater 
than 4.5%. The complete response of each upper GI symptom 
was defined as a 2 point decrease compared to pretreatment 
symptom scores or the absence of symptoms (score = 0) at the 
end of treatment.
Statistical Methods
All data were recorded and analyzed using SPSS version 17.0 
(SPSS Inc, Chicago, IL, USA). Data were expressed as mean 
and standard deviation. We used the paired and unpaired t tests 
to analyze the score differences in dyspeptic and other upper GI 
symptoms for dependent and independent samples, respectively. 
The Chi-square test was conducted to identify significant differ-
ences of the proportion between 2 categorical variables. A P-val-
ue < 0.05 indicated statistical significance.
Results
Sixty patients were enrolled. The median duration of symp-
toms in the patients was 24 (3-60) months (median [range]). All 
patients underwent upper GI endoscopy: 56 and 4 patients had 
normal endoscopic findings and mild reflux esophagitis (Los 
Angeles classification: grade A), respectively. All patients under-
went esophageal manometry, 24-hour esophageal pH monitoring 
and PPI test. The presence of each upper GI symptom at base-
line, esophageal manometry results, and the 24-hour esophageal 
pH monitoring results are described in Table 1. 
Relationship Between 24-hour Esophageal pH 
Monitoring Results and Baseline Upper Gas-
trointestinal Symptoms
The prevalence of heartburn, acid regurgitation and other 
upper GI symptoms did not differ significantly between patients 
with positive and negative pH test results, except for those with PPI Test in Overlapping NERD and FD
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Table 2. Proportion of Patients With a Complete Response For 
Each Individual Symptom After the 2-week High dose Proton 
Pump Inhibitor Treatment
Symptoms
Complete response to PPI (N/N [%])
Positive pH test Negative pH test
Heartburn 13/21 (62) 13/20 (65)
Acid regurgitation 16/28 (57) 13/17 (76)
Chest discomfort  9/22 (40)  7/19 (36)
Epigastric burning 13/24 (54)  8/17 (47)
Postprandial fullness  5/26 (19)  7/22 (32)
Early satiety sensation  7/21 (33)  6/15 (40)
Belching 13/30 (43)  6/18 (33)
Nausea 13/18 (72)  5/8 (62)
Vomiting  6/7 (85)  3/5 (60)
Food regurgitation 14/23 (60) 5/15 (33)
PPI, proton pump inhibitor.
Positive pH test vs negative pH test, P > 0.05.
Figure 2. Effects of the 2-week high dose proton pump inhibitor 
treatment on upper gastrointestinal symptom scores (*P < 0.05).
belching symptoms (Fig. 1). Patients who had positive 24-hour 
esophageal pH monitoring results were more likely to suffer from 
unwanted belching than the patients with negative pH results (P 
< 0.05). 
Effect of Proton Pump Inhibitor on Upper Gas-
trointestinal Symptoms
Heartburn, acid regurgitation, chest discomfort, epigastric 
burning, nausea and vomiting were significantly improved after 
the 2-week rabeprazole treatment compared to pretreatment 
levels. However, postprandial abdominal fullness, early satiation, 
belching and food regurgitation did not improve significantly 
(Fig. 2). 
The Association Between 24-hour Esophageal 
pH Monitoring Results and the Response of 
Upper Gastrointestinal Symptoms to Proton 
Pump Inhibitor Treatment
After the 2-week rabeprazole treatment, the proportion of pa-
tients who experienced the complete response of each GERD and 
FD symptom was not significantly different between patients 
with positive and negative 24-hour pH monitoring results (P > 
0.05) (Table 2). 
However, among each symptom score analyzed; in the pa-
tients with positive 24-hour esophageal pH monitoring results, 
heartburn, acid regurgitation, epigastric burning, nausea, chest 
discomfort and belching symptom scores at the end of treatment 
were significantly improved compared to pretreatment level (P < 
0.05) (Fig. 3A). In patients with negative pH monitoring results, 
only acid regurgitation and heartburn were significantly im-
proved, but other dyspeptic symptoms were not (Fig. 3B).
The 2-week Proton Pump Inhibitor Test Versus 
24-hour Esophageal pH Monitoring for the 
Diagnosis of Gastroesophageal Reflux Disease
After a 2-week treatment with high dose rabeprazole, 32 pa-
tients (57%) exhibited a greater than 50% improvement in typical 
reflux symptoms (heartburn and acid regurgitation); these pa-
tients were classified as the positive PPI test group. When using 
24-hour esophageal pH monitoring as the gold standard for 
GERD diagnosis, sensitivity, specificity, positive predictive val-
ue, negative predictive value and accuracy of the 2-week high 
dose rabeprazole treatment for GERD diagnosis was 47%, 38%, 
50%, 35% and 43%, respectively. 
Discussion
NERD and dyspeptic symptoms often coexist.
17 Patients 
with these overlapping conditions have lower quality of life
3 and 
higher health care costs than patients who suffer from either 
GERD or FD.
2 Acid suppression medications are usually effec-
tive for a subset of dyspeptic patients with typical reflux symp-
toms including heartburn and acid regurgitation. However, their 
efficacy in the treatment of particular upper GI symptoms such as 
post-prandial abdominal burning/pain, abdominal fullness, early Chatchai Kriengkirakul, et al
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Figure 3. Effects of the 2-week high dose proton pump inhibitor treatment on gastroesophageal reflux disease and functional dyspepsia symptom scores
in patients with positive (A) and negative (B) 24-hour esophageal pH monitoring results (*P < 0.05).
satiation and nausea has been questioned.
18,19 Our study was de-
signed to investigate whether gastric acid inhibition with a high 
dose of rabeprazole would relieve each individual upper GI 
symptom differently in non-erosive gastroesophageal reflux dis-
ease (NERD) patients with overlapping FD and to compare the 
treatment responses between patient with and without abnormal 
24-hour esophageal pH monitoring. 
Our study demonstrated that in NERD patients with dys-
peptic symptoms, 2-week high dose PPI treatment significantly 
improved epigastrium burning, nausea, vomiting, chest dis-
comfort and typical reflux symptoms including acid regurgitation 
and heartburn. However, postprandial abdominal fullness, early 
satiation, belching and food regurgitation were not significantly 
improved. We used high dose PPI to secure that acid was ad-
equately suppressed and this suggests that postprandial fullness, 
early satiation, belching and food regurgitation symptoms may 
not be acid-related symptoms. This finding supports the use of 
other medication(s) in combination with PPI as an initial treat-
ment for controlling both PPI-sensitive and PPI-resistant symp-
toms in this patient group. Two previous studies in western coun-
tries also demonstrated improvements of dyspeptic symptoms in 
FD patients who had overlapping reflux symptoms. Epigastric 
burning or pain and reflux symptoms improved after treatment 
with omeprazole (both standard dose and high dose treatment for 
2-4 weeks), but there was no significant benefit for dysmo-
tility-like symptoms including early satiety and postprandial ab-
dominal fullness.
7,8 Different results regarding regurgitation, 
belching and early satiety symptom responses to standard dose 
PPI treatment were demonstrated in previous studies.
20,21 These 
could be from different patients group enrolled. All patients en-
rolled in our study had moderate dyspepsia and moderate reflux 
symptoms combined but previous studies included patients with 
predominant reflux symptoms, not the overlapping GERD and 
dyspepsia patients. 
Acid suppressants including ranitidine, famotidine and ome-
prazole at therapeutic doses delayed solid gastric emptying in 
healthy controls.
14 A recent systematic review also found that PPI 
delayed solid gastric emptying but had an inconsistent effect on 
liquid gastric emptying.
15 Whether this slowing produces poorer 
response of delayed gastric emptying related symptoms to PPI 
treatment remains to be determined. Our study demonstrated 
that postprandial abdominal fullness, which has been shown to be 
associated with delayed gastric emptying,
22 did not respond to the 
2-week high dose PPI treatment.
Patients who receive PPI treatment may develop small bowel 
bacterial overgrowth (SIBO)
23,24 which may generate more in-
testinal gases and cause bloating. A recent study demonstrated 
that GERD patients who received esomeprazole 20 mg bid for 8 
weeks complained more of bloating and flatulence. In addition, at 
6 months after the PPI treatment, 26% of the patients developed 
SIBO.
25 The effect of PPI on the development of delayed gastric 
emptying and SIBO may explain why patients with post-prandial 
fullness, bloating, nausea/vomiting or early satiation did not re-
spond or their symptom even worsened after PPI treatment in PPI Test in Overlapping NERD and FD
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clinical practice. 
In this study, we found that 24-hour esophageal pH mon-
itoring results had no significant association with any improve-
ment in GERD or dyspeptic symptoms in overlapping GERD 
and FD. Tack et al
26 studied 24-hour esophageal pH monitoring 
in patients with FD without predominant heartburn symptoms 
and revealed that pathologic esophageal acid exposure was pres-
ent in 18.5% of FD patients without heartburn. This study also 
included gastric emptying breath test and gastric barostat study 
and demonstrated that the demographic features and the pres-
ence of putative pathophysiological mechanisms such as delayed 
gastric emptying, hypersensitivity to gastric distention, or im-
paired accommodation did not distinguish patients with and 
without pathological esophageal acid exposure. However, epi-
gastric pain was significantly more prevalent and more severe 
among patients with abnormal esophageal acid exposure than in 
patients with normal esophageal acid exposure, but the authors 
did not assess the effects of acid suppression on the symptoms. 
The other study evaluated the correlation between each dyspeptic 
symptom and esophageal acid exposure in non-erosive reflux dis-
ease patients, but they failed to find significant association be-
tween the prevalence of each dyspeptic symptom or dyspeptic 
symptom severity and esophageal acid exposure.
27 This study also 
included a 4-week trial of esomeprazole treatment (20 mg twice 
daily). The authors found that esomeprazole significantly im-
proved dyspepsia symptoms independent of the improvement in 
reflux-related symptoms and achieved similar degrees of dyspep-
sia improvement in patients with and without abnormal esoph-
ageal acid exposure. A previous randomized controlled study also 
showed that the level of esophageal acid exposure had no influ-
ence on upper abdominal pain or abdominal discomfort improve-
ment after the 2-week high dose treatment with PPI among pa-
tients with FD. These results were similar to those reported 
here.
7
The secondary aim of our study was to compare the 2-week 
PPI test and 24-hour pH monitoring for the diagnosis of GERD 
in patients with overlapping typical reflux and dyspeptic symp-
toms. We found that the PPI test had very limited value for 
GERD diagnosis in this patient group at our tertiary hospital. 
The lower sensitivity and specificity of the PPI test with respect 
to the diagnosis of GERD in our study may have been caused by 
visceral hypersensitivity, which is commonly found in NERD 
and FD.
28,29
There was no placebo group in comparison with the PPI 
group in this present study, therefore, it is difficult to conclude 
whether the symptom improvement was truly a benefit from the 
acid suppression or placebo effect. Previous randomized control 
studies
7,8 using standard dose or high dose omeprazole in patients 
with overlapping GERD and FD also demonstrated similar 
symptom improvement but lower response rate than our study. 
Another limitation was the relatively high prevalence of esoph-
ageal dysmotility which may associate with refractory regur-
gitation in our patients. This could be due to our hospital which is 
a tertiary care center and most of the subjects being refractory 
cases. The prevalence of esophageal dysmotility has been re-
ported in 35%-44% of NERD patients in tertiary hospital
30,31 
which is comparable to the result in our study. Most of the esoph-
ageal dysmotilities in our study were ineffective esophageal mo-
tility which has been reported its association with GERD. There 
is no recommendation that patients with such abnormal esoph-
ageal manometry results should be excluded before making the 
diagnosis of NERD or GERD. 
In conclusion, this study suggests that in patients with over-
lapping NERD and FD, high dose PPI (rabeprazole) is effective 
for treating the typical reflux symptoms, epigastric burning, nau-
sea, vomiting and chest discomfort but not for postprandial ab-
dominal fullness, early satiation, food regurgitation and belching 
symptoms. The assessment of distal esophageal acid exposure in 
patients with overlapping NERD and dyspepsia did not predict 
the response of symptoms to PPI. In addition, the 2-week high 
dose PPI test provides low sensitivity and low specificity for the 
diagnosis of GERD in these patients. Further randomized con-
trol studies with placebo are needed to assess which upper GI 
symptoms would truly benefit from acid-suppressive treatment 
and whether the combination of PPI and other medication(s) 
such as prokinetics as an initial treatment for overlapping NERD 
and FD is appropriate.
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